相关实验视频
Updated: May 28, 2025

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.6K
新型1,2,4-二醇衍生物希夫基衍生物:设计,合成和多酶向潜力用于治疗应用
Ibrahim Ozcan1, Hakan Alici2, Parham Taslimi3
1Karabuk University, Department of Chemistry, Faculty of Science 78050 Karabuk, Turkey.
Bioorganic chemistry
|February 9, 2025
概括
针对胆酶和碳酸酶的新希夫基衍生物显示出治疗神经退行性和代谢疾病的潜力. 这些化合物在临床应用中表现出有利的药理动力学特性.
科学领域:
- 药用化学 医学化学
- 酶抑制可以抑制酶.
- 药理学 药理学是指药理学的学科.
背景情况:
- 采用1,2,4-二醇支架的Schiff基因因其多样化的生物活动而引起兴趣.
- 向胆酶和碳酸无水酶等酶对于控制神经退行性和代谢性疾病至关重要.
研究的目的:
- 为了合成和描述新型的希夫基衍生物与1,2,4-triazole核心.
- 评估这些衍生物的体外抑制潜力,以对抗人类碳酸无水酶 (hCA) I和II,乙胆酶 (AChE) 和丁胆酶 (BChE).
- 探索这些化合物对中枢神经系统和代谢障碍的治疗前景.
主要方法:
- 希夫基衍生物的合成.
- 使用FT-IR,NMR (1H,13C,19F),质谱和元素分析进行了表征.
- 在体外酶抑制测定.
- 分子对接和动力学模拟.
- 进行ADMET (吸收,分布,新陈代谢,分泌,毒性) 分析.
主要成果:
- 化合物5a和5c对胆酶酶 (AChE和BChE) 进行了显著的抑制,这表明它们具有神经保护的潜力.
- 化合物5f和5g显示出显著的hCA I和II同酶抑制,表明有选择性的抑制能力.
- 分子对接和动力学研究证实了与酶活性部位的强烈相互作用.
- 对ADMET的分析表明,所有合成的化合物都有有利的药理动力学特性.
结论:
- 合成的希夫基衍生物是神经退行性和代谢疾病治疗干预的有希望的候选者.
- 化合物表现出对胆酶和碳酸无水酶的双重抑制潜力,为多酶向疗法铺平了道路.
- 良好的药理动力学特征支持这些化合物的潜在临床应用.
相关概念视频
Structure-Activity Relationships and Drug Design
491
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
491
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
2.9K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
2.9K

